Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | CDK4 | P11802 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15032436 | 0.87 | HTT (0.31) | HIF1AHTT | |
| SCHEMBL4420207 | 0.83 | MAPK1 (0.32) | — | |
| SCHEMBL21014329 | 0.83 | HTT (0.31) | HIF1AHTT | |
| SCHEMBL59285 | 0.80 | AR (0.36) | — | |
| SCHEMBL59286 | 0.80 | AR (0.36) | — | |
| SCHEMBL31027429 | 0.80 | L3MBTL1 (0.30) | — | |
| SCHEMBL31027422 | 0.79 | — | — | |
| SCHEMBL13790528 | 0.78 | — | — | |
| SCHEMBL6393834 | 0.78 | — | — | |
| SCHEMBL17048382 | 0.78 | USP2 (0.34) | LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3394080-B1 | LIPID-LINKED PRODRUGS | UNIV BRITISH COLUMBIA (CA) | 2023-06-07 | — | — | EP | disclosed |
| EP-3415151-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | The University of British Columbia (CA) | 2018-12-19 | — | — | EP | disclosed |
| EP-2282724-B1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | UNIV BRITISH COLUMBIA (CA) | 2018-09-05 | — | — | EP | disclosed |
| US-20180221279-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | UNIV BRITISH COLUMBIA (CA) | 2018-08-09 | — | — | US | disclosed |
| US-20180221279-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | UNIV BRITISH COLUMBIA (CA) | 2018-08-09 | — | — | US | disclosed |
| US-9968554-B2 | Modified drugs for use in liposomal nanoparticles | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2018-05-15 | — | — | US | disclosed |
| US-9968554-B2 | Modified drugs for use in liposomal nanoparticles | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2018-05-15 | — | — | US | disclosed |
| US-20140356417-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2014-12-04 | — | — | US | disclosed |
| US-8790691-B2 | Modified drugs for use in liposomal nanoparticles | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2014-07-29 | — | — | US | disclosed |
| US-8790691-B2 | Modified drugs for use in liposomal nanoparticles | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2014-07-29 | — | — | US | disclosed |
| US-20100015218-A1 | COMPOSITIONS AND METHODS FOR POTENTIATED ACTIVITY OF BIOLOGICALLY ACTIVE MOLECULES | MERCK SHARP & DOHME CORP. | 2010-01-21 | — | — | US | disclosed |
| EP-2131848-A2 | COMPOSITIONS AND METHODS FOR POTENTIATED ACTIVITY OF BIOLOGICALY ACTIVE MOLECULES | Merck & Co., Inc. (US) | 2009-12-16 | — | — | EP | disclosed |
| WO-2009141738-A2 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009141738-A2 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2009-11-26 | — | — | WO | disclosed |
| EP-2104740-A2 | LIPID NANOPARTICLE BASED COMPOSITIONS AND METHODS FOR THE DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES | Sirna Therapeutics, Inc. (US) | 2009-09-30 | — | — | EP | disclosed |
| US-20090048197-A1 | Lipid Nanoparticle Based Compositions and Methods for the Delivery of Biologically Active Molecules | SIRNA THERAPEUTICS, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| WO-2008147438-A2 | LIPID NANOPARTICLE BASED COMPOSITIONS AND METHODS FOR THE DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES | SIRNA THERAPEUTICS, INC. (US) | 2008-12-04 | — | — | WO | disclosed |
| WO-2008103276-A2 | COMPOSITIONS AND METHODS FOR POTENTIATED ACTIVITY OF BIOLOGICALY ACTIVE MOLECULES | MERCK & CO., INC. (US) | 2008-08-28 | — | — | WO | disclosed |
| US-7404969-B2 | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules | SIRNA THERAPEUTICS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-20080020058-A1 | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules | SIRNA THERAPEUTICS, INC. (US) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048197-A1 | Lipid Nanoparticle Based Compositions and Methods for the Delivery of Biologically Active Molecules | PHAX, CETP, LIPC | HIF1A 1534/4885HTT 1758/4885LMNA 442/4885 |
| US-20080020058-A1 | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules | PHAX, CETP, LIPC | HIF1A 1534/4885HTT 1758/4885LMNA 442/4885 |
| US-20180221279-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | ABCB11, SLC47A1, ABCB1 | HIF1A 3806/4885HTT 1593/4885LMNA 117/4885 |
| US-20100015218-A1 | COMPOSITIONS AND METHODS FOR POTENTIATED ACTIVITY OF BIOLOGICALLY ACTIVE MOLECULES | PHAX, MTREX, CHIA | HIF1A 1072/4885HTT 2833/4885LMNA 1129/4885 |
| US-20140356417-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | ABCB11, SLC47A1, ABCB1 | HIF1A 3806/4885HTT 1593/4885LMNA 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.